Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Dissecting Mechanisms of Action of Biologics in Inflammatory Bowel Diseases"
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: closed (30 July 2017).
Prof. Laurent Peyrin-biroulet E-Mail
Institut National de la Santé et de la Recherche Médicale U954 and Department of Gastroenterology, Nancy University Hospital, Lorraine University, France.
Interests: Crohn’s disease; ulcerative colitis; intestinal fibrosis; mucosal healing; autophagy
In the last years, new and different biological agents that target specific immunological pathways have been investigated and approved.
Strategies targeting the recruitment, adhesion and interaction of leukocytes from circulation in the gastrointestinal tract were developed, as the integrin antagonists (vedolizumab, natalizumab, etrolizumab, alicaforsen and abrilumab). Another approach is represented by agents blocking pro-inflammatory cytokines, such as ustekinumab or briakinumab, MAb targeting IL-12/IL-23 or by IL-23 selective inhibitor. Interesting results are coming from the anti-IL6 antibody in subjects with Crohn’s disease, and probably will become an antagonist of gut-specific chemokine and a selective inhibitor of matrix metalloproteinase 9 (GS-5745).
In addition to the biological agents, we observe the development of small molecules, such as mongersen (Smad7 antisense oligonucleotide) or apremilast (phosphodiesterase 4 inhibitor). Other biological targets are the tyrosine kinases inhibitors (tofacitinib or filgotinib) which play a pivotal role in cytokine receptor signaling and the sphingosine-1-phosphate receptors’ agonist (Ozanimod) which controls lymphocyte migration.
The establishment of new goals in the management of IBD and the continuation in the understanding of the pathogenetic mechanisms of IBD have allowed the development of new biological drugs and small molecules. We expect promising results and new scenarios through the study of on-going, and future, trials. Thus, with this Special Issue, we are particularly interested in articles that describe the mechanism and the specific targets of these new biological agents and their clinical applications.
Prof. Silvio Danese
Prof. Laurent Peyrin-Biroulet
Dr. Clelia Cicerone
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Inflammatory bowel disease
- Target therapy
- Biologic agents
- Small molecules
- Adhesion antagonists
- Inflammatory cytokines
- Lymphocyte control